



PRESS RELEASE

MARCY L'ETOILE, February 14, 2012 – bioMérieux issues a reminder that on January 24, 2012, it set and communicated its objectives for 2012 sales growth. The Company is targeting organic growth between 3-5% or 6-8% at constant exchange rates and including the recent acquisitions of AES and Argene. This objective is in line with the one that was set in its 2015 strategic plan communicated in 2010.

As part of its standard forecasting process, which is conducted yearly, the Company is examining the assumptions of its strategic plan for 2015.

bioMérieux's 2011 Results press release will be issued on March 13, 2012.

ABOUT BIOMERIEUX

Advancing Diagnostics to Improve Public Health

A world leader in the field of *in vitro* diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2011, revenues reached €1.427 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479).

Other information can be found at www.biomerieux.com. CONTACTS

Investor Relations

bioMérieux

Isabelle Tongio
Tél. : + 33 4 78 87 22 37
investor.relations@biomerieux.com

Media Relations

bioMérieux

Koren Wolman-Tardy
Tél (port.) : 06 13 94 51 14
media@biomerieux.com

Image Sept

Laurence Heilbronn
Tél. : + 33 1 53 70 74 64
lheilbronn@image7.fr

Albane de La Tour d'Artaise
Tél. : + 33 1 53 70 74 84
adelatour@image7.fr